Apoptotic agents from the endolichenic fungi against chemoresistant cancers
Résumé
Title: Apoptotic agents from the Endolichenic fungi against chemoresistant cancers
Autors: Makhloufi H, Gibot-Leclerc L, Millot M, Champavier Y, Pinault E, Chemin G, Mambu L,
Univ. Limoges, LABCiS, UR 22722; BISCEm, UAR 2015 US42, F-87000 Limoges, France.
Globally, cancer is a major cause of death, with breast, lung, and colon cancers being the most common. Chemoresistance is a significant hurdle in cancer treatment. Endolichenic fungi, non-pathogenic fungi located in lichens, offer a hopeful solution in the search for new bioactive compounds with anticancer potential.
The Endolichenic fungi (ELF) were previously isolated from lichens collected in Nouvelle Aquitaine Region (France). The objective is to highlight the antiproliferative potential of the Endolichenic extracts and their metabolites against colorectal cancer (HT-29) and triple-negative breast cancer (MDA-MB-231). Extracts were obtained after the cultivation of ELF strains on 3 media on a small scale.
Screening of 20 Endolichenic extracts against chemoresistant cell line HT-29 highlighted their antiproliferative potential with IC50 values ranging from 2 to 60 µg/ml (MTT Test). EtOAc extracts of Trametes versicolor and Aspergillus sp. strains were the most active with IC50 values lower than 6 µg/ml.
Solid-state fermentation (10 L, SAB) of T. versicolor produced 5 g of EtOAc extract. Its Liquid-liquid extraction offered two fractions. The evaluation of their antiproliferative activity showed that hexane fraction has moderate activity with an IC50 of 16µg/ml and methanol fraction has an IC50 = 3µg/ml. The LC-MS/MS analysis of extract and fractions reveals very few matches in the MS database.
The bioactive compounds are currently being isolated, and their bioactivity will be tested through apoptosis studies on MDA-MB231 and HT-29 cells.
Domaines
CancerOrigine | Fichiers produits par l'(les) auteur(s) |
---|